NewAmsterdam Pharma Company NV
NAMS29.980USD
-1.270-4.06%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
2.45BMarket Cap
LossP/E TTM
More Details of NewAmsterdam Pharma Company NV Company
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV Info
Ticker SymbolNAMS
Company nameNewAmsterdam Pharma Company NV
IPO dateNov 23, 2022
CEODavidson (Michael Harvey)
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 23
AddressGooimeer 2-35
CityNAARDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1411 DC
Phone31352062971
Websitehttps://ir.newamsterdampharma.com/
Ticker SymbolNAMS
IPO dateNov 23, 2022
CEODavidson (Michael Harvey)
Company Executives of NewAmsterdam Pharma Company NV
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
-46.55%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
-46.55%
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
-346.55%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
-46.55%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
-46.55%
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
-346.55%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
14.74%
Capital World Investors
8.68%
RA Capital Management, LP
8.31%
Forbion Capital Partners
8.00%
Fidelity Management & Research Company LLC
5.11%
Other
55.16%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
14.74%
Capital World Investors
8.68%
RA Capital Management, LP
8.31%
Forbion Capital Partners
8.00%
Fidelity Management & Research Company LLC
5.11%
Other
55.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.43%
Investment Advisor/Hedge Fund
21.92%
Venture Capital
19.83%
Private Equity
14.74%
Hedge Fund
12.59%
Family Office
2.67%
Research Firm
2.55%
Individual Investor
1.01%
Sovereign Wealth Fund
0.99%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
317
118.25M
104.29%
-6.54M
2025Q3
283
121.74M
107.54%
+4.12M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
16.70M
14.73%
--
--
Nov 01, 2025
Capital World Investors
9.82M
8.66%
+1.43M
+17.11%
Sep 30, 2025
RA Capital Management, LP
10.14M
8.94%
--
--
Sep 30, 2025
Forbion Capital Partners
9.21M
8.12%
-1.37M
-12.92%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.39M
4.76%
+3.57M
+195.28%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
5.67M
5%
-4.80M
-45.83%
Dec 02, 2025
Wellington Management Company, LLP
4.02M
3.55%
+697.13K
+20.98%
Sep 30, 2025
Viking Global Investors LP
6.48M
5.71%
-503.00K
-7.21%
Sep 30, 2025
Deerfield Management Company, L.P.
4.27M
3.76%
-849.26K
-16.60%
Sep 30, 2025
Jennison Associates LLC
4.20M
3.7%
+1.25M
+42.51%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Guru Index ETF
1.82%
ALPS Medical Breakthroughs ETF
1.81%
Virtus LifeSci Biotech Clinical Trials ETF
1.22%
First Trust Small Cap Growth AlphaDEX Fund
1.05%
First Trust NASDAQ Pharmaceuticals ETF
0.83%
Capital Group US Small and Mid Cap ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
0.55%
First Trust Small Cap Core Alphadex Fund
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
View more
Global X Guru Index ETF
Proportion1.82%
ALPS Medical Breakthroughs ETF
Proportion1.81%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.22%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.05%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.83%
Capital Group US Small and Mid Cap ETF
Proportion0.68%
ProShares Ultra Nasdaq Biotechnology
Proportion0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.55%
First Trust Small Cap Core Alphadex Fund
Proportion0.43%
Invesco Nasdaq Biotechnology ETF
Proportion0.42%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
